Severe thrombocytopenia without major haemorrhage in dengue in a patient on dual antiplatelet therapy; a real world clinical experience

Dengue is endemic in tropical regions and bleeding, ranging from minor to life-threatening, is a dreaded complication. With the increasing incidence of atherosclerotic cardiovascular disease in low- to middle-income countries where Dengue is prevalent, whether to stop or continue antiplatelet agents in patients with thrombocytopenia is a clinical conundrum.